Difference between revisions of "Hepatocyte nuclear factor-1beta"

From Libre Pathology
Jump to navigation Jump to search
(+PDAC)
 
(5 intermediate revisions by the same user not shown)
Line 4: Line 4:
*[[Clear cell carcinoma of the ovary]].
*[[Clear cell carcinoma of the ovary]].
*[[Renal cell carcinoma]]s - including [[clear cell renal cell carcinoma]].<ref name=pmid26574638>{{cite journal |authors=Hanley KZ, Cohen C, Osunkoya AO |title=Hepatocyte Nuclear Factor-1β Expression in Clear Cell Renal Cell Carcinoma and Urothelial Carcinoma With Clear Cell Features: A Potential Diagnostic Pitfall |journal=Appl. Immunohistochem. Mol. Morphol. |volume=25 |issue=2 |pages=134–138 |date=February 2017 |pmid=26574638 |doi=10.1097/PAI.0000000000000279 |url=}}</ref><ref name=pmid32150988>{{cite journal |authors=Kim M, Joo JW, Lee SJ, Cho YA, Park CK, Cho NH |title=Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes |journal=Cancers (Basel) |volume=12 |issue=3 |pages= |date=March 2020 |pmid=32150988 |pmc=7139472 |doi=10.3390/cancers12030602 |url=}}</ref>
*[[Renal cell carcinoma]]s - including [[clear cell renal cell carcinoma]].<ref name=pmid26574638>{{cite journal |authors=Hanley KZ, Cohen C, Osunkoya AO |title=Hepatocyte Nuclear Factor-1β Expression in Clear Cell Renal Cell Carcinoma and Urothelial Carcinoma With Clear Cell Features: A Potential Diagnostic Pitfall |journal=Appl. Immunohistochem. Mol. Morphol. |volume=25 |issue=2 |pages=134–138 |date=February 2017 |pmid=26574638 |doi=10.1097/PAI.0000000000000279 |url=}}</ref><ref name=pmid32150988>{{cite journal |authors=Kim M, Joo JW, Lee SJ, Cho YA, Park CK, Cho NH |title=Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes |journal=Cancers (Basel) |volume=12 |issue=3 |pages= |date=March 2020 |pmid=32150988 |pmc=7139472 |doi=10.3390/cancers12030602 |url=}}</ref>
*[[Pancreatic ductal adenocarcinoma]].<ref name=pmid30065837>{{cite journal |vauthors=Yang MX, Coates RF, Ambaye A, Gardner JA, Zubarick R, Gao Y, Skelly J, Liu JG, Mino-Kenudson M |title=Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma |journal=Biomark Res |volume=6 |issue= |pages=25 |date=2018 |pmid=30065837 |pmc=6062876 |doi=10.1186/s40364-018-0139-6 |url=}}</ref>
*[[Pancreatic ductal adenocarcinoma]] and other [[foregut primary carcinomas]].<ref name=pmid30065837>{{cite journal |authors=Yang MX, Coates RF, Ambaye A, Gardner JA, Zubarick R, Gao Y, Skelly J, Liu JG, Mino-Kenudson M |title=Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma |journal=Biomark Res |volume=6 |issue= |pages=25 |date=2018 |pmid=30065837 |pmc=6062876 |doi=10.1186/s40364-018-0139-6 |url=}}</ref>


Note:
Note:
*CA-125, RCCma, and CD10 can help distinguish ''clear cell renal cell carcinoma'' and  ''Müllerian clear cell tumours''.<ref name=pmid25279712>{{cite journal |authors=Mentrikoski MJ, Wendroth SM, Wick MR |title=Immunohistochemical distinction of renal cell carcinoma from other carcinomas with clear-cell histomorphology: utility of CD10 and CA-125 in addition to PAX-2, PAX-8, RCCma, and adipophilin |journal=Appl Immunohistochem Mol Morphol |volume=22 |issue=9 |pages=635–41 |date=October 2014 |pmid=25279712 |doi=10.1097/PAI.0000000000000004 |url=}}</ref>
*CA-125, RCCma, and CD10 can help distinguish ''clear cell renal cell carcinoma'' and  ''Müllerian clear cell tumours''.<ref name=pmid25279712>{{cite journal |authors=Mentrikoski MJ, Wendroth SM, Wick MR |title=Immunohistochemical distinction of renal cell carcinoma from other carcinomas with clear-cell histomorphology: utility of CD10 and CA-125 in addition to PAX-2, PAX-8, RCCma, and adipophilin |journal=Appl Immunohistochem Mol Morphol |volume=22 |issue=9 |pages=635–41 |date=October 2014 |pmid=25279712 |doi=10.1097/PAI.0000000000000004 |url=}}</ref>
===Occasionally positive===
*[[Lung adenocarcinoma]].<ref name=pmid30065837/>
*[[Prostate adenocarcinoma]].<ref name=pmid30065837/>
*Gastroesophageal adenocarcinoma.<ref name=pmid30065837/>


==Negative==
==Negative==
*[[Serous carcinoma of the ovary]].
*[[Serous carcinoma of the ovary]].
*[[Hepatocellular carcinoma]].<ref name=pmid30065837/>
*[[Colorectal adenocarcinoma]].<ref name=pmid30065837/>
*[[Breast adenocarcinoma]].<ref name=pmid30065837/>
*[[Lung squamous cell carcinoma]].<ref name=pmid30065837/>


==References==
==References==
{{Reflist|1}}
{{Reflist|2}}


[[Category:Immunohistochemistry]]
[[Category:Immunohistochemistry]]

Latest revision as of 17:29, 5 August 2021

Hepatocyte nuclear factor-1beta, abbreviated HNF-1beta and HNF-1β, is an immunostain that marks clear cell carcinoma of the ovary.

Positive

Note:

  • CA-125, RCCma, and CD10 can help distinguish clear cell renal cell carcinoma and Müllerian clear cell tumours.[4]

Occasionally positive

Negative

References

  1. Hanley KZ, Cohen C, Osunkoya AO (February 2017). "Hepatocyte Nuclear Factor-1β Expression in Clear Cell Renal Cell Carcinoma and Urothelial Carcinoma With Clear Cell Features: A Potential Diagnostic Pitfall". Appl. Immunohistochem. Mol. Morphol. 25 (2): 134–138. doi:10.1097/PAI.0000000000000279. PMID 26574638.
  2. Kim M, Joo JW, Lee SJ, Cho YA, Park CK, Cho NH (March 2020). "Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes". Cancers (Basel) 12 (3). doi:10.3390/cancers12030602. PMC 7139472. PMID 32150988. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139472/.
  3. 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 Yang MX, Coates RF, Ambaye A, Gardner JA, Zubarick R, Gao Y, Skelly J, Liu JG, Mino-Kenudson M (2018). "Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma". Biomark Res 6: 25. doi:10.1186/s40364-018-0139-6. PMC 6062876. PMID 30065837. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062876/.
  4. Mentrikoski MJ, Wendroth SM, Wick MR (October 2014). "Immunohistochemical distinction of renal cell carcinoma from other carcinomas with clear-cell histomorphology: utility of CD10 and CA-125 in addition to PAX-2, PAX-8, RCCma, and adipophilin". Appl Immunohistochem Mol Morphol 22 (9): 635–41. doi:10.1097/PAI.0000000000000004. PMID 25279712.